ClinicalTrials.gg
Active, not recruitingNCT06642935ENHANCEUpdated May 29, 2026

A Study to Explore Improved Features and a Simplified Treatment Approach for a Totally Implantable Cochlear Implant (TICI) Research System in Adults With Severe Hearing Loss

An interventional study of Totally implantable cochlear Implant in Hearing Loss, Bilateral or Unilateral, Hearing Loss, Sensorineural and Hearing Loss, Cochlear, sponsored by Cochlear. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Primary conditionHearing Loss, SensorineuralRegistry: Hearing LossReclassifiedWhy we changed it
Registry
Hearing Loss — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hearing Loss, Sensorineural
Why
  1. The study's listed conditions name Hearing Loss, Sensorineural, a narrower term within Hearing Loss.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cochlear · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 32 studies in Hearing Loss, Sensorineural by Cochlear — 2 open to participants now, 6 under way, none of them phase 3. Hearing Loss, Sensorineural · Cochlear.

Enrollment
17th of 28
18 · median 22
Started
2024
with 3 others
No phase
28 of 32
1 open now
Registered
27th of 32
by date

Among the 32 studies in Hearing Loss, Sensorineural by Cochlear, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2024, is one of 28 with no phase, and was the 27th registered.

Hearing Loss, Sensorineural

346 studies on the registry are indexed under Hearing Loss, Sensorineural; 101 are open to participants now.

Browse Hearing Loss, Sensorineural studies →

Open to participants now

2 of the 32 studies in Hearing Loss, Sensorineural by Cochlear are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Hearing Loss, Sensorineural by Cochlear, or all of them as a file.
02

Study summary

This clinical study will test a new investigational totally implanted cochlear implant system (TICI G2). The cochlear implant has an implantable microphone under the skin to detect speech and sound from the environment allowing hearing without the need of any external parts. This study will explore new ways to process the sound from the implanted microphone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing and overall general health.

03

Conditions studied

  • Hearing Loss, Bilateral or Unilateral
  • Hearing Loss, Sensorineural
  • Hearing Loss, Cochlear

Browse trials for

Keywords

  • cochlear implant
  • sensorineural hearing loss
04

In context

Hearing Loss, Sensorineural Reclassified

346 studies on the registry are indexed under Hearing Loss, Sensorineural; 101 are open to participants now.

This study's enrollment of 18 is below the median of 32 across 247 interventional studies indexed under Hearing Loss, Sensorineural.

Browse Hearing Loss, Sensorineural studies →

Lead sponsor

Cochlear is the lead sponsor of 92 studies on the registry; 9 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Compared within Hearing Loss, Sensorineural, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hearing Loss. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older, at time of consent
  • Candidate for cochlear implantation as assessed by the implanting clinic
  • Fluent in English, as determined by the investigator
  • Willing to participate in and comply with all requirements of the protocol
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Severe, or poorer, bilateral sensorineural hearing loss prior to five years of age, as reported by the subject
  • Duration of severe to profound hearing loss greater than 20 years in the ear to be implanted as reported by the subject or by audiometric history, if available
  • Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array
  • Deafness due to lesions of the acoustic nerve affecting the ear to be implanted
  • Medical or psychological conditions that would contraindicate undergoing anaesthesia, surgery or participation in the clinical investigation, as determined by the investigator
  • Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the investigator
  • Unrealistic expectations on the part of the subject regarding the possible benefits, risks and limitations that are inherent to the surgical procedure and prosthetic device, as determined by the investigator
  • Desire to use an integrated acoustic component post-implantation
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling
  • Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation.
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an drug or device (unless Cochlear sponsored and determined by investigator or Sponsor to not impact this investigation)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Device :TICI G2 Clinical Investigation System

    Totally implantable cochlear Implant

    Device: Totally implantable cochlear Implant

Interventions

  • DeviceTotally implantable cochlear Implant

    Totally implantable cochlear Implant

07

What researchers measure

Primary outcomes

  1. Mean change in the cochlear implant internal microphone frequency gain response over time

    The mean gain (dB) averaged across the frequency range (0.125 to 8kHz) of the internal cochlear implant microphone measured at 1 day, 7 days, 14 days, 21 days, 8 weeks (60 days), 12 weeks (90 days), 52 weeks (12 months) and 77 weeks (18 months) post-implantation surgery

    Time frame: 1 day, 7 days, 14 days, 21 days, 8 weeks (60 days), 12 weeks (90 days), 52 weeks (12 months) and 77 weeks (18 months) post-implantation surgery

08

Study locations

1 site
  • Royal Victoria Eye and Ear Hospital
    Melbourne, Victoria 3002, Australia
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2027, 36 months after the start.

Of 80 industry-sponsored interventional studies with no phase under Hearing Loss, Sensorineural, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 23. This study's planned 36 months is above that.

Counting every sponsor, half of 162 studies reached it within 22 months; a quarter within 6 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2024
First posted
Oct 15, 2024
StartActual
Nov 18, 2024
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06642935
Lead sponsor
Cochlear
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Nov 18, 2024
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
May 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion